PMID- 37553232
OWN - NLM
STAT- MEDLINE
DCOM- 20231106
LR  - 20231106
IS  - 1447-0756 (Electronic)
IS  - 1341-8076 (Linking)
VI  - 49
IP  - 11
DP  - 2023 Nov
TI  - Minimal clinically important difference of the Functional Living Index-Emesis in 
      patients with gynecological malignant tumor: A post hoc analysis of a single-arm 
      study.
PG  - 2711-2716
LID - 10.1111/jog.15769 [doi]
AB  - AIM: This study aimed to explore the impact of minimum clinically important 
      difference (MCID) of the Functional Living Index-Emesis (FLIE) in patients with 
      gynecologic malignancies. METHOD: This post hoc analysis included patients with 
      gynecological malignant tumors in the Department of Oncology of our hospital 
      between October 2020 and October 2021. RESULTS: A total of 149 patients (aged 
      50.05 +/- 12.24 years) were included. Most of the patients were married (75.8%), 
      lived in the city (60.4%), and had a history of motion sickness (75.8%). The 
      degree of nausea (9.00 [0.00, 16.00] vs. 30.00 [16.00, 48.00], P < 0.001) and 
      vomiting (9.00 [0.00, 16.00] vs. 30.00 [16.00, 48.00], P < 0.001) were 
      significantly improved after treatment. Taking the options in the scale as the 
      subjective anchor, the MCID of FLIE for nausea and vomiting were 28.5 and 29 in 
      anchor-based analysis, respectively. In the distribution-based analysis, the MCID 
      of FLIE for nausea and vomiting were 2.41, 6.04, and 9.66; and 2.31, 5.78, and 
      9.24 in effect size of 0.2, 0.5, and 0.8, respectively. CONCLUSION: The MCID of 
      FLIE for nausea and vomiting in patients with gynecological malignant tumors was 
      28.5 and 29 in the anchor-based analysis, with higher specificity, and 6.04 and 
      5.78 in the distribution-based analysis, with higher sensitivity. The development 
      of the MCID scale might be used to interpret the clinical significance of 
      chemotherapy-induced nausea and vomiting in patients with gynecological 
      malignancies and help to calculate the sample size for future clinical trials.
CI  - (c) 2023 Japan Society of Obstetrics and Gynecology.
FAU - Fan, Tingting
AU  - Fan T
AUID- ORCID: 0000-0002-0296-9515
AD  - Oncology Department, Affiliated People's Hospital of Jiangsu University, 
      Zhenjiang, China.
FAU - Luo, Caifeng
AU  - Luo C
AD  - Department of Nursing, Medical College of Jiangsu University, Zhenjiang, China.
LA  - eng
PT  - Journal Article
DEP - 20230808
PL  - Australia
TA  - J Obstet Gynaecol Res
JT  - The journal of obstetrics and gynaecology research
JID - 9612761
RN  - 0 (Antiemetics)
RN  - 0 (Antineoplastic Agents)
SB  - IM
MH  - Humans
MH  - Female
MH  - Vomiting/chemically induced
MH  - *Antiemetics
MH  - *Antineoplastic Agents/therapeutic use
MH  - Minimal Clinically Important Difference
MH  - Quality of Life
MH  - Nausea/chemically induced
MH  - *Genital Neoplasms, Female/complications/drug therapy
OTO - NOTNLM
OT  - CINV
OT  - FLIE
OT  - chemotherapy
OT  - gynecological malignancies
OT  - post hoc analysis
EDAT- 2023/08/09 01:05
MHDA- 2023/11/06 06:43
CRDT- 2023/08/08 21:23
PHST- 2023/01/16 00:00 [received]
PHST- 2023/07/26 00:00 [accepted]
PHST- 2023/11/06 06:43 [medline]
PHST- 2023/08/09 01:05 [pubmed]
PHST- 2023/08/08 21:23 [entrez]
AID - 10.1111/jog.15769 [doi]
PST - ppublish
SO  - J Obstet Gynaecol Res. 2023 Nov;49(11):2711-2716. doi: 10.1111/jog.15769. Epub 
      2023 Aug 8.